754 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Golden State Wealth Management LLC

Golden State Wealth Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 754 shares of the biopharmaceutical company’s stock, valued at approximately $70,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth about $25,000. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the last quarter. Valued Wealth Advisors LLC grew its holdings in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares in the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences in the 4th quarter valued at approximately $28,000. Finally, Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the 4th quarter valued at $29,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $95.48 on Tuesday. The company has a market capitalization of $118.99 billion, a price-to-earnings ratio of 1,060.89, a P/E/G ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock’s fifty day simple moving average is $93.04 and its 200-day simple moving average is $86.86.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on GILD. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Piper Sandler boosted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Finally, Truist Financial increased their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 142,180 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock valued at $53,611,715 in the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.